Sanara Medtech, Inc. (SMTI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$32.33+0.50%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · SMTI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -7.1% |
| Our one-year growth estimate | diamond | 16.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 24.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 11 industry peers
SMTI — litigation filed
Dated 2026-10-16
Other Events. As previously announced, Sanara MedTech Inc., a Texas corporation (the “Company” or “Sanara”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with MiMedx Group, Inc., a Florida corporation (“MiMedx”), and Mustang Merger Sub, Inc., a wholly-owned subsidiary of MiMedx (“Merger Subsidiary”), pursuant to which, among other things and subject to the terms and conditions of the Merger Agreement, Merger Subsidiary will be merged with and into the Company (the “Me…
Why it matters: The October 16 filing reports litigation tied to the merger. A court order that delays or blocks the deal could affect its planned closing.
Worry ifA court order or company filing says the lawsuit blocks or delays the merger past year-end 2026.
Less concerning ifA court filing dismisses the suit, or Sanara reports no court order has delayed the merger by year-end 2026.
Why it matters: Q2 operating income fell from $2.5 million to $1.8 million as expenses rose. A recovery would ease concern about cost growth.
Supportive ifA later quarter reports operating income above $2.5 million. That was the Q2 2025 level.
Worry ifA later quarter reports operating income at or below $1.8 million. That was the Q2 2026 level.
Why it matters: Soft tissue products drove Q2 growth, while bone fusion sales fell. Continued soft tissue growth would support the main sales trend.
Supportive ifQ3 soft tissue repair sales grow year over year, with total revenue above Q3 2025.
Worry ifQ3 soft tissue repair sales fall year over year, or total revenue is below Q3 2025.
Why it matters: OsStic would add a new bone-fixation product. A launch on time would show progress beyond Sanara's current products.
Supportive ifSanara or MiMedx confirms OsStic is for sale in Q1 2027.
Worry ifA company update moves the launch past Q1 2027 or says the launch is paused.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$27 on $10,000 · ±0.3% | How much price usually moves either way. |
| Bad day | $479 loss on $10,000 · 4.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,210 loss on $10,000 · 42.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Q2 revenue grew 9%, while first-half revenue grew 14%. Q3 results will show whether growth stays near the full-year plan.
Watch forOn the November 11 results, year-to-date revenue is on pace for $116 million to $121 million in 2026.
Also watch forSanara cuts its $116 million to $121 million 2026 revenue range, or year-to-date results fall below its pace.